Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides

Vaccine

Volumn 22, Issue 20, 2004, Pages 2641-2650

  Wang, Yiqiang ^a   Krieg, Arthur M ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Autoimmune disease; CpG motif; Tolerance

Indexed keywords

ANTIGEN; AUTOANTIBODY; CD69 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; HEN EGG LYSOZYME ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOZYME; OLIGODEOXYNUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODY FORMATION; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CPG ISLANDS; DNA; IMMUNE TOLERANCE; MICE; MURAMIDASE; OLIGODEOXYRIBONUCLEOTIDES;

EID: 2942618418     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.055     Document Type: Article

References (60)

1. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72(4):1984;955-962
2. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374(6522):1995;546-549
3. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20:2002;709-760
4. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162(4):1999;2291-2298
5. Krieg A.M., Love-Homan L., Yi A.K., Harty J.T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161(5):1998;2428-2434
6. Corral R.S., Petray P.B. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine. 19(2-3):2000;234-242
7. Moss R.B., Diveley J., Jensen F.C., Gouveia E., Carlo D.J. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. J. Hum. Virol. 4(1):2001;39-43
8. Deml L., Schirmbeck R., Reimann J., Wolf H., Wagner R. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin. Chem. Lab Med. 37(3):1999;199-204
9. Hirunpetcharat C., Wipasa J., Sakkhachornphop S., Nitkumhan T., Zheng Y.Z., Pichyangkul S. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine. 21(21-22):2003;2923-2932
10. Davis H.L., Suparto I.I., Weeratna R.R., Iskandriati D.D., Chamzah S.S., Ma'ruf A.A. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 18(18):2000;1920-1924
11. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3):2000;1617-1624
12. McCluskie M.J., Weeratna R.D., Payette P.J., Davis H.L. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol. Med. Microbiol. 32(3):2002;179-185
13. Malanchere-Bres E., Payette P.J., Mancini M., Tiollais P., Davis H.L., Michel M.L. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J. Virol. 75(14):2001;6482-6491
14. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 21(19-20):2003;2461-2467
15. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18(17):2000;1755-1762
16. Stern B.V., Boehm B.O., Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. J. Immunol. 168(12):2002;6099-6105
17. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168(3):2002;1212-1218
18. Liu H.M., Newbrough S.E., Bhatia S.K., Dahle C.E., Krieg A.M., Weiner G.J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood. 92(10):1998;3730-3736
19. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U.S.A. 94(20):1997;10833-10837
20. Davila E., Celis E. Repeated administration of cytosine- phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165(1):2000;539-547
21. Heckelsmiller K., Beck S., Rall K., Sipos B., Schlamp A., Tuma E. Combined dendritic cell- and CpG-oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32(11):2002;3235-3245
22. Carpentier A.F., Chen L., Maltonti F., Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59(21):1999;5429-5432
23. Carpentier A.F., Xie J., Mokhtari K., Delattre J.Y. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res. 6(6):2000;2469-2473
24. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., Hammerling G.J. NK and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167(9):2001;5247-5253
25. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Waldschmidt M. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167(9):2001;4878-4886
26. Auf G., Carpentier A.F., Chen L., Le Clanche C., Delattre J.Y. Implication of macrophages in tumor rejection induced by CpG- oligodeoxynucleotides without antigen. Clin. Cancer Res. 7(11):2001;3540-3543
27. Hafner M., Zawatzky R., Hirtreiter C., Buurman W.A., Echtenacher B., Hehlgans T. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 61(14):2001;5523-5528
28. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9(7):2003;831-835
29. Krieg A.M. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol. 15(6):1995;284-292
30. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3(11):2002;999-1005
31. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 416(6881):2002;603-607
32. Wang Y., Krieg A.M. Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int. Immunol. 15(2):2003;223-231
33. Vinuesa C.G., Goodnow C.C. Immunology: DNA drives autoimmunity. Nature. 416(6881):2002;595-598
34. Krieg A.M. A role for Toll in autoimmunity. Nat. Immunol. 3(5):2002;423-424
35. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science. 280(5361):1998;243-248
36. Kouskoff V., Lacaud G., Nemazee D. T cell-independent rescue of B lymphocytes from peripheral immune tolerance. Science. 287(5462):2000;2501-2503
37. von Herrath M.G., Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 3(3):2003;223-232
38. Goodnow C.C., Crosbie J., Adelstein S. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 334(6184):1988;676-682
39. Goodnow C.C., Crosbie J., Jorgensen H., Brink R.A., Basten A. Induction of self-tolerance in mature peripheral B lymphocytes. Nature. 342(6248):1989;385-391
40. Fulcher D.A., Basten A. Whither the anergic B-cell? Autoimmunity. 19(2):1994;135-140
41. Goodnow C.C., Brink R., Adams E. Breakdown of self-tolerance in anergic B lymphocytes. Nature. 352(6335):1991;532-536
42. Healy J.I., Dolmetsch R.E., Timmerman L.A., Cyster J.G., Thomas J.L., Crabtree G.R. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity. 6(4):1997;419-428
43. de Vos A.F., Fukushima A., Lobanoff M.C., Vistica B.P., Lai J.C., Grivel J.C. Breakdown of tolerance to a neo-self antigen in double transgenic mice in which B cells present the antigen. J. Immunol. 164(9):2000;4594-4600
44. Gapin L., Cabaniols J.P., Cibotti R., Ojcius D.M., Kourilsky P., Kanellopoulos J.M. Determinant selection for T-cell tolerance in HEL-transgenic mice: dissociation between immunogenicity and tolerogenicity. Cell Immunol. 177(1):1997;77-85
45. Fulcher D.A., Lyons A.B., Korn S.L., Cook M.C., Koleda C., Parish C. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Exp. Med. 183(5):1996;2313-2328
46. Cook M.C., Basten A., Fazekas de St G.B. Rescue of self-reactive B cells by provision of T cell help in vivo. Eur. J. Immunol. 28(8):1998;2549-2558
47. Yule T.D., Basten A., Allen P.M. Hen egg-white lysozyme-specific T cells elicited in hen egg-white lysozyme-transgenic mice retain an imprint of self-tolerance. J. Immunol. 151(6):1993;3057-3069
48. Cibotti R., Kanellopoulos J.M., Cabaniols J.P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc. Natl. Acad. Sci. U.S.A. 89(1):1992;416-420
49. Rui L., Vinuesa C.G., Blasioli J., Goodnow C.C. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat. Immunol. 4(6):2003;594-600
50. Deng C., Radu C., Diab A., Tsen M.F., Hussain R., Cowdery J.S. IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J. Immunol. 170(6):2003;2833-2842
51. Jones D.E., Palmer J.M., Burt A.D., Walker C., Robe A.J., Kirby J.A. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology. 36(3):2002;679-686
52. Sacher T., Knolle P., Nichterlein T., Arnold B., Hammerling G.J., Limmer A. CpG-ODN-induced inflammation is sufficient to cause T-cell-mediated autoaggression against hepatocytes. Eur. J. Immunol. 32(12):2002;3628-3637
53. Wirth S., Guidotti L.G., Ando K., Schlicht H.J., Chisari F.V. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J. Immunol. 154(5):1995;2504-2515
54. Akkaraju S., Ho W.Y., Leong D., Canaan K., Davis M.M., Goodnow C.C. A range of CD4 T cell tolerance: partial inactivation to organ-specific antigen allows non-destructive thyroiditis or insulitis. Immunity. 7(2):1997;255-271
55. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27(9):1997;2340-2344
56. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160(2):1998;870-876
57. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186(10):1997;1623-1631
58. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 19(4-5):2000;413-422
59. Roman M., Martin-Orozco E., Goodman J.S. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3(8):1997;849-854
60. Sano K., Shirota H., Terui T., Hattori T., Tamura G. Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of th2 differentiation in a sequence-independent manner. J. Immunol. 170(5):2003;2367-2373